Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,920Price:$4.11
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,800Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,800Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:214,797Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:214,797Price:--
-
Dec 31, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-82,790Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-52,206Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-23,216Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-28,783Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-24,187Price:$5.35
Filings by filing date
-
Mar 06, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-9,920Price:$4.11
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,800Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Cote JenniferOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,800Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:214,797Price:--
-
Mar 05, 2024 (filed on Mar 07, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:214,797Price:--
-
Dec 31, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-82,790Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-52,206Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-23,216Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-28,783Price:$5.35
-
Dec 29, 2023 (filed on Jan 03, 2024)Insider Name:Green James WOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-24,187Price:$5.35
News
Biz Brief
Sector: Healthcare | Industry: Advanced Medical Equipment & Technology |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 84 OCTOBER HILL RD HOLLISTON MA 01746 |
Tel: | N/A |
Website: | https://www.harvardbioscience.com |
IR: | See website |
Key People | ||
James W. Green Chairman of the Board, President, Chief Executive Officer | Jennifer Cote Chief Financial Officer, Treasurer |
Business Overview |
Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance. |
Financial Overview |
For the fiscal year ended 31 December 2023, Harvard Bioscience, Inc. revenues decreased 1% to $112.3M. Net loss decreased 64% to $3.4M. Revenues reflect Instruments, equipment, software and accessories segment decrease of 2% to $105.7M, Rest of The World segment decrease of 22% to $12.8M, United States segment decrease of 3% to $48.2M. Lower net loss reflects Restructuring Charges & Provisions decrease of 78% to $320K (expense), Selling/General/Admin. |
Employees: | 391 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $189.46M as of Dec 31, 2023 |
Annual revenue (TTM): | $112.25M as of Dec 31, 2023 |
EBITDA (TTM): | $8.89M as of Dec 31, 2023 |
Net annual income (TTM): | -$3.42M as of Dec 31, 2023 |
Free cash flow (TTM): | $11.72M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $32.28M as of Dec 31, 2023 |
Shares outstanding: | 43,421,251 as of Mar 20, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |